

# Yishai Ofran

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5039045/publications.pdf>

Version: 2024-02-01

85  
papers

2,014  
citations

304743

22  
h-index

276875

41  
g-index

86  
all docs

86  
docs citations

86  
times ranked

2764  
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 224-231.	2.4	5
2	Early death in acute promyelocytic leukemia: time to redefine risk groups. <i>Haematologica</i> , 2022, , .	3.5	0
3	Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment. <i>Experimental Hematology</i> , 2022, 107, 20-23.	0.4	10
4	Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 71.	6.2	12
5	Cytogenetics or MRD in B-cell ALL. Do both reign supreme?. <i>Leukemia</i> , 2022, 36, 1201-1202.	7.2	0
6	Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	5
7	A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA+ HR-MDS (SELECT-MDS-1).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7075-TPS7075.	1.6	3
8	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. <i>Leukemia</i> , 2021, 35, 62-74.	7.2	63
9	BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. <i>Cancer</i> , 2021, 127, 1246-1259.	4.1	21
10	Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission. <i>European Journal of Haematology</i> , 2021, 106, 64-71.	2.2	3
11	Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance. <i>Cancer Cell International</i> , 2021, 21, 53.	4.1	25
12	A chemotherapy-free regimen for Philadelphia chromosome-positive acute lymphoblastic leukemia: are we there yet?. <i>Haematologica</i> , 2021, 106, 1781-1782.	3.5	0
13	Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. <i>Leukemia</i> , 2021, 35, 1529-1538.	7.2	48
14	Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. <i>American Journal of Hematology</i> , 2021, 96, 790-795.	4.1	20
15	Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021, Volume 11, 41-54.	2.7	8
16	Daratumumab: new indications revolving around <i>off-targets</i>. <i>Haematologica</i> , 2021, 106, 3032-3033.	3.5	3
17	The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors. <i>Nature Communications</i> , 2021, 12, 5397.	12.8	20
18	Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samples. <i>Cell Systems</i> , 2021, , .	6.2	3

#	ARTICLE	IF	CITATIONS
19	Spontaneous arising of a lymphoblastoid Bâ€cell line harbouring a preâ€leukemic DNMT3A mutation in acute myeloid leukaemia cell culture. Journal of Cellular and Molecular Medicine, 2021, 25, 10778-10782.	3.6	0
20	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021, 138, 2753-2767.	1.4	305
21	Homozygosity for CHEK2 p.Gly167Arg leads to a unique cancer syndrome with multiple complex chromosomal translocations in peripheral blood karyotype. Journal of Medical Genetics, 2020, 57, 500-504.	3.2	12
22	Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia. Leukemia, 2020, 34, 293-295.	7.2	54
23	Bone marrow blast elimination by the fifth day of 7â€%+â€%3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61â€%years of age: A longâ€term followâ€up of a multiâ€center prospective study. American Journal of Hematology, 2020, 95, E3-E5.	4.1	0
24	Transthoracic parametric Doppler for bedside diagnosis of pulmonary embolism: A pilot study. Journal of Clinical Ultrasound, 2020, 48, 204-210.	0.8	1
25	Low risk for viral reactivation during induction for acute myeloid leukemia in patients with resolved hepatitis B infection. Leukemia and Lymphoma, 2020, 61, 1260-1262.	1.3	0
26	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. New England Journal of Medicine, 2020, 383, 2526-2537.	27.0	265
27	Venetoclax is safe and efficacious in relapsed/refractory AML. Leukemia and Lymphoma, 2020, 61, 2221-2225.	1.3	30
28	Safety and efficacy of blinatumomab: a real world data. Annals of Hematology, 2020, 99, 835-838.	1.8	19
29	How we treat older patients with acute myeloid leukaemia. British Journal of Haematology, 2020, 191, 682-691.	2.5	3
30	ERK Activity in Immature Leukemic Cells Drives Clonal Selection during Induction Therapy for Acute Myeloid Leukemia. Scientific Reports, 2020, 10, 8349.	3.3	5
31	First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study. Blood, 2020, 136, 27-28.	1.4	3
32	RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors. Blood, 2020, 136, 31-32.	1.4	0
33	Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. Blood, 2020, 136, 33-35.	1.4	1
34	How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica, 2019, 104, 2135-2143.	3.5	22
35	Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remissionâ€”a multi-center historical control study. Annals of Hematology, 2019, 98, 2711-2717.	1.8	13
36	Palliative care service incorporated in a hematology department: a working model fostering changes in clinical practice. Leukemia and Lymphoma, 2019, 60, 2079-2081.	1.3	6

#	ARTICLE	IF	CITATIONS
37	The role of specialized hospital units in infection and mortality risk reduction among patients with hematological cancers. PLoS ONE, 2019, 14, e0211694.	2.5	2
38	Baseline Chest Computed Tomography for Early Diagnosis of Invasive Pulmonary Aspergillosis in Hemato-oncological Patients: A Prospective Cohort Study. Clinical Infectious Diseases, 2019, 69, 1805-1808.	5.8	22
39	Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation. Leukemia and Lymphoma, 2019, 60, 2449-2456.	1.3	14
40	BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study. Blood Advances, 2019, 3, 3740-3749.	5.2	10
41	Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission – a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2019, 184, 643-646.	2.5	8
42	Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML. Blood, 2019, 134, 5091-5091.	1.4	1
43	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study. Blood, 2019, 134, 115-115.	1.4	19
44	The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission. Blood, 2019, 134, LBA-3-LBA-3.	1.4	68
45	Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse. Blood, 2018, 132, 5206-5206.	1.4	6
46	Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation – a retrospective national multicenter study. Annals of Hematology, 2017, 96, 575-579.	1.8	5
47	Grb2 regulates the proliferation of hematopoietic stem and progenitors cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 2449-2459.	4.1	10
48	BCR-ABL (Ph)-like acute leukemia – Pathogenesis, diagnosis and therapeutic options. Blood Reviews, 2017, 31, 11-16.	5.7	62
49	Activated kinases in ALL: time to act. Blood, 2017, 129, 3280-3282.	1.4	2
50	Anti-herpesvirus prophylaxis versus placebo, no treatment or pre-emptive treatment in hemato-oncological malignancies. The Cochrane Library, 2017, , .	2.8	0
51	Is the D14 bone marrow in acute myeloid leukemia still the gold standard?. Current Opinion in Hematology, 2016, 23, 108-114.	2.5	4
52	How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood, 2016, 128, 488-496.	1.4	45
53	Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS) – ViLen-01 protocol. Annals of Hematology, 2016, 95, 1811-1818.	1.8	5
54	Final Phase IIa Study Results Evaluating the CXCR4 Antagonist BL-8040 in Combination with Cytarabine (Ara-C) for the Treatment of Relapsed/Refractory AML Patients. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S28.	0.4	1

#	ARTICLE	IF	CITATIONS
55	Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 975-981.	2.0	29
56	The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 2745-2745.	1.4	3
57	Acute leukaemias. , 2016, , 699-753.		0
58	Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study. <i>Blood</i> , 2016, 128, 1650-1650.	1.4	0
59	Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the 3+7 induction regimen for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, 1159-1164.	4.1	22
60	Introducing minimal residual disease in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2015, 22, 139-145.	2.5	10
61	Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3146-3153.	3.0	53
62	Higher Infection Rate After 7- Compared With 5-Day Cycle of Azacitidine in Patients With Higher-Risk Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e95-e99.	0.4	18
63	The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2546-2546.	1.4	15
64	Relapse Mechanism of FLT3-ITD Positive AML and Cell Differentiation Blockage. <i>Blood</i> , 2015, 126, 4961-4961.	1.4	0
65	Genetic Stratification in Myeloid Diseases: From Risk Assessment to Clinical Decision Support Tool. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0025.	1.0	1
66	Acute Myeloid Leukemia in Adolescents and Young Adults: Challenging Aspects. <i>Acta Haematologica</i> , 2014, 132, 292-297.	1.4	28
67	Concealed dagger in FLT3/ITD+ AML. <i>Blood</i> , 2014, 124, 2317-2319.	1.4	5
68	BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. <i>Blood</i> , 2014, 124, 950-950.	1.4	11
69	Immature Platelet Fraction Predicts Outcome and Sepsis Development in Critically Ill Patients Admitted to a General Intensive Care Unit, but Not in Neutropenic Patients. <i>Blood</i> , 2014, 124, 2164-2164.	1.4	2
70	Genetic profiling in acute myeloid leukaemia – where are we and what is its role in patient management. <i>British Journal of Haematology</i> , 2013, 160, 303-320.	2.5	47
71	Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: A retrospective multicenter study. <i>American Journal of Hematology</i> , 2013, 88, 130-134.	4.1	59
72	Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. <i>Leukemia Research</i> , 2013, 37, 1004-1009.	0.8	98

#	ARTICLE	IF	CITATIONS
73	Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial. American Journal of Infection Control, 2013, 41, 1167-1172.	2.3	72
74	Early Bone Marrow Examination, On The Fifth Day Of Induction For AML, Is Highly Predictive Of Response. Blood, 2013, 122, 3893-3893.	1.4	1
75	Treatment for relapsed acute myeloid leukemia. Current Opinion in Hematology, 2012, 19, 89-94.	2.5	35
76	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: Risk stratified approach with a long-term follow-up. American Journal of Hematology, 2012, 87, 875-879.	4.1	6
77	Patterns of Information-Seeking for Cancer on the Internet: An Analysis of Real World Data. PLoS ONE, 2012, 7, e45921.	2.5	58
78	Induction and postremission strategies in acute myeloid leukemia: what is new?. Current Opinion in Hematology, 2011, 18, 83-88.	2.5	14
79	Administration of All-Trans Retinoic Acid (ATRA) to Newly Diagnosed Patients (pts) with Acute Promyelocytic Leukemia (APL) Is Delayed Even At Experienced Centers and Associated with An Increased Early Death Rate (EDR): A Retrospective Analysis of 205 Pts. Blood, 2011, 118, 942-942.	1.4	0
80	Diverse Patterns of T-Cell Response against Multiple Newly Identified Human Y Chromosome-Encoded Minor Histocompatibility Epitopes. Clinical Cancer Research, 2010, 16, 1642-1651.	7.0	33
81	Near-Fatal Amitraz Intoxication: The Overlooked Pesticide. Basic and Clinical Pharmacology and Toxicology, 2005, 97, 185-187.	2.5	33
82	The predictive value of admission and follow up factor V and VII levels in patients with acute hepatitis and coagulopathy. Journal of Hepatology, 2005, 42, 82-86.	3.7	45
83	To Be a Doctor in Jerusalem: Life under Threat of Terrorism. Annals of Internal Medicine, 2004, 140, 307.	3.9	7
84	A Doctor's Duties in Terror-Struck Communities. AMA Journal of Ethics, 2004, 6, 248.	0.7	0
85	Effect of Scrapie Infection on the Activity of Neuronal Nitric-oxide Synthase in Brain and Neuroblastoma Cells. Journal of Biological Chemistry, 1996, 271, 16856-16861.	3.4	36